397 related articles for article (PubMed ID: 18206214)
1. B-cell-directed therapies in systemic lupus erythematosus.
Tieng AT; Peeva E
Semin Arthritis Rheum; 2008 Dec; 38(3):218-27. PubMed ID: 18206214
[TBL] [Abstract][Full Text] [Related]
2. New treatments for SLE: cell-depleting and anti-cytokine therapies.
Anolik JH; Aringer M
Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
[TBL] [Abstract][Full Text] [Related]
3. The immunological basis of B-cell therapy in systemic lupus erythematosus.
Mok MY
Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380
[TBL] [Abstract][Full Text] [Related]
4. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
5. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.
Murdaca G; Colombo BM; Puppo F
Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271
[TBL] [Abstract][Full Text] [Related]
6. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
8. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?
Dolff S; Abdulahad WH; Bijl M; Kallenberg CG
Lupus; 2009 Jun; 18(7):575-80. PubMed ID: 19433456
[TBL] [Abstract][Full Text] [Related]
9. Anticytokine therapy in systemic lupus erythematosus.
Yoo DH
Lupus; 2010 Oct; 19(12):1460-7. PubMed ID: 20947558
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls.
Jacobi AM; Goldenberg DM; Hiepe F; Radbruch A; Burmester GR; Dörner T
Ann Rheum Dis; 2008 Apr; 67(4):450-7. PubMed ID: 17673490
[TBL] [Abstract][Full Text] [Related]
11. B cells in SLE: different biological drugs for different pathogenic mechanisms.
Diamanti AP; Rosado MM; Carsetti R; Valesini G
Autoimmun Rev; 2007 Dec; 7(2):143-8. PubMed ID: 18035325
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
13. Biologics in the treatment of systemic lupus erythematosus.
Lateef A; Petri M
Curr Opin Rheumatol; 2010 Sep; 22(5):504-9. PubMed ID: 20502332
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.
Lee HJ; Sinha AA
Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022
[TBL] [Abstract][Full Text] [Related]
15. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
Stohl W; Looney RJ
Clin Immunol; 2006 Oct; 121(1):1-12. PubMed ID: 16697258
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A; White AJ
Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
[TBL] [Abstract][Full Text] [Related]
17. Use of rituximab in patients with systemic lupus erythematosus: an update.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
[TBL] [Abstract][Full Text] [Related]
18. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
Levesque MC; St Clair EW
J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
[TBL] [Abstract][Full Text] [Related]
19. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
Dörner T
J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
[TBL] [Abstract][Full Text] [Related]
20. Treatment of systemic lupus erythematosus: new advances in targeted therapy.
Lo MS; Tsokos GC
Ann N Y Acad Sci; 2012 Jan; 1247():138-52. PubMed ID: 22236448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
